J Cancer 2014; 5(2):151-155. doi:10.7150/jca.8412

Research Paper

Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study

Ju-Yin Chen1,2, Shou-Jen Kuo2, Yung-Po Liaw3, Itzhak Avital4, Alexander Stojadinovic4, Yan-gao Man4, Ciaran Mannion5, Jianlian Wang6, Ming-Chih Chou7,8, Horng-Der Tsai9, Shou-Tung Chen2✉, Yi-Hsuan Hsiao7,9 ✉

1. Department of Epidemiology, School of Public Health, University of California Los Angeles, USA.
2. Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, Taiwan.
3. Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung, Taiwan.
4. Bon Secours Cancer Institute, Bon Secours Health System, Richmond, VA, USA.
5. Department of Pathology, Hackensack University Medical Center, Hackensack, NJ, USA.
6. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
7. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
8. Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
9. Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan.

Abstract

Background: Our study aimed to assess the endometrial cancer risk after tamoxifen adjuvant treatment for female breast cancer patients in Taiwan.

Materials and Methods: A total of 74,280 breast cancer patients between January 1997 and December 2004 were included in the study; 39,411 received tamoxifen treatment and 34,869 did not. Tamoxifen-associated endometrial cancer was defined as endometrial cancer that occurred in patients at least 6-month after the diagnosis of breast cancer, who underwent tamoxifen treatment.

Results: A total of 222 patients developed endometrial cancer, and of these,153 (69 %) were seen in patients with tamoxifen treatment, and 69 (31%) were seen in patients without the use of tamoxifen. The incidence of endometrial cancer was 0.388% (153/39,411) in patients with tamoxifen treatment, while was 0.198% (69/34,869) in patients without tamoxifen treatment. Logistic regression analysis demonstrated that tamoxifen use and age over 35 years were significantly correlated with development of endometrial cancer (p<0.001 and p=0.002, respectively). The odds ratio was 2.94 (95%CI, 2.13-4.06) for 3 years or longer tamoxifen use. The odds ratio was 4.08 (95%CI, 1.67-9.93) for women older than 35 years compared to those 35 or younger than 35 years. There were no significant differences in prior hormone exposure, hypertension and diabetes.

Conclusions: To the best of our knowledge, this is the largest population based study that shows in patients with breast cancer, tamoxifen use for more than three years or patients older than 35 years was associated with a significantly increased risk for developing endometrial cancer.

Keywords: breast cancer, tamoxifen, endometrial cancer

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Chen JY, Kuo SJ, Liaw YP, Avital I, Stojadinovic A, Man Yg, Mannion C, Wang J, Chou MC, Tsai HD, Chen ST, Hsiao YH. Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study. J Cancer 2014; 5(2):151-155. doi:10.7150/jca.8412. Available from http://www.jcancer.org/v05p0151.htm